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Cyclosporine nephrotoxicity remains a major side effect in
solid organ transplantation, and can be exacerbated by
concomitant administration of sirolimus. Cyclosporine
and sirolimus are P-glycoprotein (Pgp) substrates. We
hypothesized that the Pgp activity level may affect
cyclosporine cytotoxicity by interfering with the ability of
Pgp to remove cyclosporine from within tubular cells, and
that an interaction between cyclosporine and sirolimus on
Pgp function may explain the enhancement of cyclosporine
nephrotoxicity by sirolimus. Cyclosporine cytotoxicity was
evaluated in primary cultures of normal human renal
epithelial cells (HRECs) by cell viability and cytotoxicity
assays. Verapamil, quinine, PSC833, and PGP-4008 were used
as Pgp inhibitors. Rhodamine-123 (R-123), a fluorescent
substrate of Pgp, was used to assess Pgp-mediated transport.
Cellular cyclosporine concentration was measured by
high-performance liquid chromatography coupled to tandem
mass spectrometry. Pgp expression and function were
confirmed in HRECs and cyclosporine and sirolimus were
shown to be Pgp inhibitors in this model. Verapamil-induced
inhibition of Pgp led to a significant increase in cellular
concentration of cyclosporine (Po0.05). Cyclosporine exerted
a concentration-dependent cytotoxic effect on HRECs that
was significantly increased by inhibition of Pgp activity.
Sirolimus exerted an inhibitory effect on R-123 efflux in
HRECs and increased cellular cyclosporine concentrations in a
dose-dependent manner. These data demonstrate that Pgp
plays a critical role in protecting renal epithelial cells from
cyclosporine toxicity. The inhibitory effect of sirolimus on
Pgp-mediated efflux and the cellular concentration of
cyclosporine could explain the exacerbation of cyclosporine
nephrotoxicity observed clinically.
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Cyclosporine A, a member of the calcineurin inhibitor class
of drugs, remains a mainstay of immunosuppressive regi-
mens to prevent allograft rejection following solid organ
transplantation.1 In renal transplantation, the major limiting
factor for use of cyclosporine is nephrotoxicity, which may
reduce the overall benefit of cyclosporine therapy with
respect to long-term graft survival.2 In a prospective study of
the natural history of chronic allograft nephropathy,
cyclosporine appeared to be the chief cause of late ongoing
histologic injury, even in grafts with excellent early histologic
findings.3 Two forms of cyclosporine nephrotoxicity have
been described. Acute (or ‘functional’) nephrotoxicity is
mediated by an imbalance of vasoconstrictors and vasodila-
tors within the renal vasculature, leading to vasoconstriction
and sustained renal ischemia.2 Chronic (or ‘structural’)
cyclosporine nephropathy is defined as irreversible renal
dysfunction associated with morphological injuries such as
tubular atrophy, interstitial fibrosis and arteriolar hyalinosis.4
Cyclosporine may induce these changes by promoting
multiple, inter-related pathophysiological processes.5 A
combination of cyclosporine-induced hemodynamic changes
and direct toxic effects of cyclosporine on tubular epithelial
cells is thought to play a role in the development of
interstitial fibrosis via the release of factors such as
transforming growth factor-beta, endothelin-1, plasminogen
activator inhibitor-type 1, inducing fibroblast proliferation,
and matrix synthesis.6 Cyclosporine may also activate
apoptosis genes and increase apoptosis in tubular and
interstitial cells, thereby inducing tubular atrophy.7
Another mechanism that may contribute to cyclosporine-
related nephrotoxicity, but which has not been completely
explored, involves the P-glycoprotein (Pgp). The ABCB1
(previously multidrug-resistance-1) gene product Pgp is a
membrane protein, which functions as an ATP-dependent
exporter of intracellular xenobiotics. Its importance was first
recognized as a consequence of its role in the development of
multidrug resistance in cultured tumor cells against various
anticancer agents. In the kidney, Pgp is constitutively
expressed on the brush border of the proximal tubular cells
and on the distal tubule8 and it has been suggested that
Pgp may be instrumental in cyclosporine nephrotoxicity.
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Cyclosporine is a substrate of Pgp,9 and variations in
expression and/or function of Pgp could lead to accumula-
tion of cyclosporine, along with other cytotoxic agents,
within the tubular cells. In support of this hypothesis,
immunohistological studies by Del Moral et al.10 have shown
an inverse relationship between cyclosporine deposits in renal
tissue and the level of Pgp expression in proximal tubular
cells in animal models, suggesting that the normal Pgp
response may be defective in patients susceptible to
cyclosporine-related nephrotoxicity, leading to retention of
excess amounts of cyclosporine in the cells.11,10 More
recently, Koziolek et al.8 showed that low expression of Pgp
in renal parenchymal cells was associated with the occurrence
of cyclosporine nephrotoxicity. Moreover, a ABCB1 poly-
morphism in kidney allograft donors, which is associated
with decreased expression of Pgp in renal tissue, has been
shown an independent risk factor for the development of
cyclosporine-related nephrotoxicity.12 Together, these find-
ings suggest that factors that modulate Pgp expression may
have an impact on cyclosporine-related nephrotoxicity by
causing an accumulation of cyclosporine within the renal cells.
The new immunosuppressive agent sirolimus is also a Pgp
substrate,13 and an interaction between cyclosporine and
sirolimus is seen clinically. Although perceived as a non-
nephrotoxic drug, administration of sirolimus reduces renal
function when given concomitantly with cyclosporine.14 We
hypothesized that Pgp may be the site of this interaction.
Experimental studies in salt-depleted rats have demonstrated
that sirolimus increases intrarenal cyclosporine concentra-
tions to a greater extent than blood concentration of
cyclosporine.15 In addition, even subtherapeutic doses of
cyclosporine and sirolimus exert a synergistic effect on the
development of chronic nephrotoxicity in rats16 and recent
studies have shown that administration of sirolimus around
the time of renal injury can exacerbate the injury and delay
repair, an effect that may be due to a potent antiproliferative
effect of sirolimus on renal tubular cells.17
We therefore postulated that an interaction between
cyclosporine and sirolimus could limit Pgp-mediated drug
efflux and increase cyclosporine cytotoxicity by limiting the
removal of cyclosporine from tubular cells. The present study
was undertaken using human renal epithelial cells (HRECs)
in primary culture to investigate firstly, whether impaired
Pgp function may contribute to nephrotoxicity by interfering
with the ability of Pgp to remove cyclosporine from the
tubular cell, thereby increasing cyclosporine intracellular
toxicity, and secondly, to assess the effect of sirolimus on
Pgp-mediated efflux of cyclosporine.
RESULTS
Expression of Pgp in HRECs
Expression of Pgp by the HRECs was confirmed with
Western blot analysis of crude membranes using the anti-
Pgp monoclonal antibody C219. Results showed varying
levels of expression of Pgp on the crude membrane from
different kidneys (Figure 1a).
To ensure that the efflux properties of Pgp are not altered
by the isolation procedure or culture of HRECs, Pgp activity
was evaluated by measuring the effect of Pgp inhibition on
cellular efflux of the fluorescent Pgp substrate R123 in the
presence or absence of 40 mM verapamil. Figure 1b plots the
decrease in intracellular fluorescence in a time-dependent
manner. Cellular fluorescence decreased by 40% after an
efflux time of 30 min without verapamil, a reduction that was
dramatically attenuated in the presence of verapamil. Pgp
blockage limited the efflux to o10% after 120 min.
Effect of cyclosporine on Pgp-mediated efflux
In the absence of cyclosporine, 55% of R123 remained within
HRECs after an efflux time of 30 min. Cyclosporine increased
cellular retention of R123 in a concentration-dependent
manner (Figure 2a). The maximum inhibitory effect was
obtained with clinically relevant concentrations of cyclos-
porine concentrations (41 mM), above which R123 efflux was
almost entirely blocked and R123 intracellular retention was
90%.
In order to analyze the consequences of Pgp inhibition on
cyclosporine accumulation, intracellular concentration of
cyclosporine was measured after varying durations of cellular
efflux, with and without verapamil. Cyclosporine concentra-
tion gradually decreased over 60 min (Figure 2b). In the
presence of verapamil, this decrease was dramatically
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Figure 1 | Expression and function of Pgp in normal HRECs.
(a) Immunoblot analysis of Pgp in crude membranes from HL60R
cells, overexpressing Pgp and used as positive controls (left) and
from HRECs derived from three different kidneys using the C219
monoclonal anti-Pgp antibody (10 mg/ml). (b) Immunoblotting for
actin confirmed equal loading for HREC samples Cellular efflux of
R-123. with or without the Pgp inhibitor verapamil. Cells were
preloaded for 1 h with 5 mg/ml R-123 and thereafter incubated with
R-123-free medium with verapamil 40 mM (triangles) or without
verapamil (squares). Intracellular fluorescence was quantified at
successive timepoints after the removal of R-123 from the medium.
Results are expressed as percentage of the initial intracellular
fluorescence, corrected by the total protein content of each sample,
before any R-123 efflux. All determinations were performed in
triplicate plates. Data shown represent the mean7s.e.m. of five
independent experiments performed with cells from three different
kidneys.
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curtailed, with a 50% increase in cyclosporine intracellular
concentration (Po0.01) (Figure 2c).
Effect of Pgp inhibition on cyclosporine cytoxicity
3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium assay showed that cyclos-
porine reduced viable cell numbers in a dose-dependent
manner compared to vehicle-treated cells (Figure 3a). Four
unrelated Pgp inhibitors, even though they have no cytotoxic
effect on HRECs, significantly decreased the LC50 of
cyclosporine (i.e. the concentration needed to decrease cell
viability by 50%). As shown in Figure 3a, the LC50 of
cyclosporine decreased from 7.470.5 to 3.770.5 and
5.970.1 mM, when the two highly specific Pgp inhibitors
PSC833 and Pgp-4008 were added in the culture medium,
respectively (Po0.01). Similar results were obtained by
measuring lactate dehydrogenase (LDH) release in the
medium (Figure 3b).
Effect of sirolimus on Pgp-mediated efflux and intracellular
cyclosporine retention
In the absence of sirolimus, 55% of R123 was retained within
the HRECs after an efflux time of 30 min. The addition of
sirolimus resulted in concentration-dependent intracellular
retention of R123, with a maximal inhibitory concentration
of 1mM (Figure 4). Sirolimus also induced concentration-
dependent intracellular retention of cyclosporine, with a
sirolimus dose of 5 mM resulting in 80% increase in
cyclosporine concentration within the HRECs after 30 min
efflux time (Figure 5).
DISCUSSION
Cyclosporine remains a pivotal immunosuppressive drug in
renal transplantation. However, the side effects of cyclospor-
ine include nephrotoxicity, which is one of the major causes
of late allograft loss. Although many in vitro and in vivo
studies have explored the pathological changes induced by
cyclosporine nephrotoxicity, such as its fibrogenic effects,
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Figure 2 | Cyclosporine transport by Pgp. (a) HRECs were preloaded
with 5 mg/ml R-123 and incubated with R-123-free medium
containing increasing concentrations of cyclosporine (0–5 mM).
Intracellular fluorescence was quantified, and corrected by the total
protein content of each sample, after an efflux time of 30 min.
Results were expressed as percentage of intracellular fluorescence
before any efflux. Data shown represent the mean7s.e.m. of six
independent experiments performed with cells from four different
kidneys. (b) Cells were preloaded for 2 h with 0.5 mM cyclosporine
and incubated with cyclosporine-free medium with 40 mM verapamil
(white squares) or without verapamil (black squares). Intracellular
cyclosporine concentration was measured at successive timepoints
after removal of cyclosporine (see Materials and Methods). Data
shown represent the mean7s.e.m. of two independent experiments
performed with cells from two different kidneys. (c) Cells were
preloaded for 2 h with 0.5 mM cyclosporine and incubated with
cyclosporine-free medium with or without 40 mM verapamil.
Intracellular cyclosporine concentration was measured 30 min after
removal of cyclosporine. Data are expressed as a percentage of
cyclosporine concentration after 30 min efflux time in the absence
of verapamil, and represent the mean7s.e.m. of four independent
experiments performed with cells from three different kidneys.
**Pp0.01 (Mann–Whitney test).
a
b
Cyclosporine (M)
Ce
ll v
ia
bi
lity
(%
 of
 un
tre
ate
d c
ell
s)
0
20
40
60
80
100
0 10
*
*
Cyclosporine (M)
LD
H
 re
le
as
ed
/to
ta
l (%
)
0
20
40
60
80
100
120 CsA aloneCsA+PSC 833
CsA+Pgp 6004
CsA+verapamil
CsA+quinine
*
*
*
8642
0 108642
Figure 3 | Impact of Pgp inhibition on cyclosporine-induced
cytotoxicity in normal HRECs. (a) HRECs, seeded in 96-well plates,
were cultured with complete medium containing cyclosporine
(CsA, 0–10 mM) in the presence or absence of Pgp inhibitors (40mM
verapamil, 5 mM PSC833, 5 mg/ml Pgp-4008 or 50 mM quinine). After
incubation at 371C for 6 days, the relative number of living cells was
determined by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay. The effect of
cyclosporine is expressed as percentage cell viability compared to
untreated cells. *Pp0.05 (Mann–Whitney test) for all inhibitor-treated
cells versus cells treated with cyclosporine alone. (b) HRECs, seeded in
96-well plates, were cultured with complete medium containing
cyclosporine (0–10 mM) in the presence (black bars) or absence (white
bars) of 40 mM verapamil. Cytotoxicity was quantified by LDH release
into the culture medium. The effect of cyclosporine is expressed as
percentage of LDH released into the culture medium compared to
total LDH content. Data represent the mean7s.e.m. of three
independent experiments performed with cells from three
different kidneys. *Pp0.05; **Pp0.01 (Mann–Whitney test).
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secretion of vasoactive compounds and the direct tubular cell
toxicity caused by apoptosis or necrosis,5,18 the mechanisms
underlying these changes remains undefined. In the current
study, we have examined the role of the export protein Pgp
on susceptibility to nephrotoxicity in HRECs in order to
investigate the location of the cyclosporine–sirolimus inter-
action within renal cells. Our results demonstrate that Pgp
protects human renal tubular cells from the cytotoxic effect of
cyclosporine and suggest that Pgp may be the site of the
interaction between cyclosporine and sirolimus.
Several studies have previously investigated a causal
relationship between renal Pgp expression and function,
intrarenal cyclosporine accumulation, and drug-induced
nephrotoxicity. Preliminary experiments in human kidney
tissue confirmed the presence of Pgp in proximal and distal
tubular cells using immunohistochemistry techniques. More-
over, Koziolek et al.8 demonstrated that significantly lower
Pgp expression was observed in allograft biopsies from
patients with cyclosporine nephrotoxicity compared to
patients with biopsy-proven acute tubular necrosis, acute
vascular or chronic allograft rejection who did not have
cyclosporine-related toxicity.8 In an animal model, it was
shown that intrarenal angiotensin II deposits, peritubular
fibrosis, and cyclosporine deposits were inversely related to
renal Pgp expression in rats receiving cyclosporine, that is,
the lower the expression of Pgp in tubular cells, the greater
the histologic signs of severe nephrotoxicity.10 These data
suggest that cyclosporine elimination from tubular cells by
Pgp represents a detoxification process.19 It thus seems clear
that low expression of Pgp in renal graft tissue leads to
insufficient clearance of cyclosporine from the cells, thereby
leading to an accumulation of cyclosporine with consequent
nephrotoxic effects. Although these histopathologic data
suggest a role for Pgp in detoxification of renal tubular cells,
demonstration of a direct link to Pgp was still lacking. To our
knowledge, our study is the first to prove that Pgp is a
detoxicating factor for cyclosporine in human renal tubular
cells, and that blocking Pgp-mediated transport by Pgp
inhibitors increased cyclosporine cytotoxicity.
According to this hypothesis, different patterns of Pgp
expression may account for variations in susceptibility to
cyclosporine nephrotoxicity between individuals. Although
variability owing to the cell isolation procedure cannot be
excluded, we confirmed the interindividual variability in Pgp
expression in HRECs prepared from different subjects by
both Western blot (Figure 1) and Northern blot (data not
shown). Numerous studies have already demonstrated a high
interindividual variability in Pgp expression in the kidney,20
liver,21 and intestine.22 These interindividual variations in
Pgp expression may be due to genetic factors;23 one of these,
which may alter Pgp expression, has recently been associated
with susceptibility to cyclosporine-related nephrotoxicity.12
Other ABC proteins might contribute to the efflux process
we studied. ABC-transporters recognized for their ability to
modulate drug resistance and toxicity of xenobiotics include
multidrug resistance-associated protein (MRP)1, MRP2, and
BCRP.24–26 BCRP is not expressed in the human kidney.25 In
the kidney, MRP1 has been showed to be mainly expressed at
the basolateral membranes of distal tubular cells.27–29 This
particular distribution raises questions about its physiological
significance in cellular protection from toxic xenobiotics.27
MRP2 is expressed by the proximal tubular brush border in
human kidney and plays an important role in tubular cell
detoxication.29 However, the increased cyclosporine cyto-
toxicity we observed with the two highly specific Pgp
inhibitors Pgp-4008 and PSC833, that inhibit neither
MRP1 nor MRP2,30–32 strongly suggest the pivotal role of
Pgp on cyclosporine cellular efflux, and that MRP1 and
MRP2 are not involved in this efflux process.
Sirolimus is a potent new immunosuppressive agent that
modulates the immune response at different targets to those
of cyclosporine. To minimize cyclosporine dose-dependent
toxicities, and to augment the therapeutic efficacy of
cyclosporine-based immunosuppressive regimens, several
clinical studies have evaluated combination therapy with
sirolimus. However, a 1-year phase III clinical trial revealed
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Figure 5 | Effect of sirolimus on intracellular cyclosporine
accumulation. HRECs were preloaded with 0.5mM cyclosporine for
2 h, after which increasing concentrations of sirolimus were added in
a cyclosporine-free medium. Intracellular cyclosporine concentration
was measured 60 min after removal of cyclosporine from the medium
(see Materials and Methods). All determinations were performed
in triplicate plates. Data represent the mean7s.e.m. of four
independent experiments performed with cells from three
different kidneys.
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Figure 4 | Effect of sirolimus on Pgp-mediated efflux. HRECs were
preloaded with 5 mg/ml R-123 for 1 h and thereafter incubated
with R-123-free medium containing increasing concentrations of
sirolimus (0–5 mM). Intracellular fluorescence was quantified, and
corrected by the total protein content of each sample, after an
efflux time of 30 min. Data are expressed as percentage of
intracellular fluorescence before any efflux and represent the
mean7s.e.m. of four independent experiments performed with
cells from four different kidneys.
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that sirolimus (2 or 5 mg) with full-dose cyclosporine
resulted in higher serum creatinine concentrations and lower
creatinine clearance than cyclosporine with azathioprine.14
Another study gave very similar results,33 and together the
results of these trials led to the European Agency for the
Evaluation of Medicinal Products recommendation to with-
draw cyclosporine from sirolimus-treated patients at 3 months.
The potentiation of CNI-induced nephrotoxicity by
sirolimus has been confirmed in animal models.16,34,35
Sirolimus does not appear to be nephrotoxic when used
alone, but potentiates the nephrotoxic effects of cyclosporine
even when cyclosporine is given at low doses. To date, the
most frequent explanation for this interaction has been
pharmacokinetics, that is, sirolimus increases cyclosporine
exposure. This suggestion was supported by the observation
that significantly lower cyclosporine doses were required to
achieve target concentrations of cyclosporine in sirolimus-
treated patients versus those given azathioprine in the pivotal
US trial,14 but in the registration studies blood concentra-
tions of cyclosporine were similar with sirolimus, azathio-
prine, or placebo.14,33 A local interaction between sirolimus
and cyclosporine within the kidney was firstly suggested by
Napoli et al.36 Using a rat model, they demonstrated that a
pharmacokinetic interaction between sirolimus and cyclo-
sporine increases the concentrations of both agents in whole
blood and, especially, in the renal tissue. More recently,
Podder et al.15, reported that combined administration of
various doses of cyclosporine and sirolimus in rats increased
cyclosporine whole-blood concentrations compared to cyclo-
sporine alone, but that the effect was even greater in kidney
tissue. At each dose of cyclosporine, intrarenal cyclosporine
concentration increased when animals were given sirolimus
concomitantly. This led to speculation that a pharmaco-
kinetic interaction between sirolimus and cyclosporine may
alter cyclosporine exposure to a greater extent in the kidney
than in the blood, thus explaining the results of the
registration trials. In accordance with this hypothesis, in
our study, the effects of sirolimus on Pgp-mediated efflux
and on cyclosporine intracellular concentration suggest that
the increased cyclosporine nephrotoxicity seen clinically in
patients receiving sirolimus may be due to inhibition of
Pgp-mediated cyclosporine cellular efflux in HRECs by
sirolimus. We tried to study the effect of sirolimus on the
cytotoxicity induced by cyclosporine and discovered that
sirolimus was responsible for an antiproliferative effect by
itself on HRECs.17 This anti-proliferative effect did not allow
us to study the impact of sirolimus on the cytotoxicity
induced by cyclosporine in this cellular model.
The main limitation of the present study remains the
difficulties to extrapolate the results of an in vitro study to in
vivo effects in treated patients. In clinical practice, intrarenal
cyclosporine and sirolimus concentrations during conven-
tional immunosuppressive treatment are currently unknown.
As cyclosporine and sirolimus are lipophilic compounds,
their respective concentrations might be higher in the cellular
membrane than in blood. It is then difficult to ensure that
in vitro concentrations we used have an in vivo relevance. In
various experiments, HRECs were loaded with a non-toxic
cyclosporine concentration of 0.5 mM, already used in other
in vitro models of cyclosporine toxicity.37–39 Concerning
sirolimus, the concentration ranges were also in accordance
with previous studies that have evaluated Pgp inhibition by
sirolimus,13,40 as well as the potentiation of cyclosporine
nephrotoxicity by sirolimus in vivo.15
In conclusion, these results confirm in an in vitro model of
HRECs, that Pgp plays a critical role in protecting renal
epithelial cells from cyclosporine toxicity. Moreover sirolimus
inhibits Pgp-mediated efflux and leads to cyclosporine
intracellular accumulation in HRECs. These results suggest
that Pgp could play a role in the in situ interaction between
cyclosporine and sirolimus, that would lead to the potentia-
tion of cyclosporine nephrotoxicity by sirolimus seen
clinically.
MATERIALS AND METHODS
Reagents and antibodies
Sirolimus was donated by Wyeth Research (Monmouth Junction,
NJ, USA). Cyclosporine and PSC833 were donated by Novartis
Pharma AG (Basel, Switzerland). All other chemicals were obtained
from Sigma-Aldrich (Saint Quentin Fallavier, France). Cyclosporine,
sirolimus, PGP-4008, and PSC833 were diluted in ethanol and
verapamil in water. The cell culture medium and the other cell
culture products were obtained from Life Technologies (Cergy
Pontoise, France). C219 monoclonal antibody was purchased from
DAKO (Trappes, France). Anti-actin antibody was obtained from
Sigma (Saint Quentin Fallavier, France).
Cell culture
Normal HRECs were harvested from human nephrectomy speci-
mens removed for renal cell carcinoma, and isolated according to
previously published methods, with minor modifications.14,15,41,42
Fragments of non-malignant renal cortex were minced and digested
with collagenase IV (250 IU/ml) for 3 h at 371C. Cells were
centrifuged and the pellets washed three times with phosphate-
buffered saline (PBS). Cells were then cultured in Dulbecco’s
modified Eagle’s medium containing 5 mg/ml insulin, 10 mg/ml
human apotransferrin, 500 ng/ml hydrocortisone, 10 ng/ml epider-
mal growth factor, 6.5 ng/ml triiodothyronin, 5 ng/ml sodium
selenite, 1% fetal calf serum, 25 IU/ml penicillin, 25 mg/ml
streptomycin and 10 mM N-2-hydroxyethylpiperazine-N0-2-ethane-
sulfonic acid buffer. Cells were incubated at 371C in 5% CO2 and
95% air. The characterization of our cellular model has been
published previously,17 confirming the proximal descent of the vast
majority of the cultured tubular epithelial cells. Experiments were
not performed with cells beyond the third passage as it has been
shown that no phenotypic changes occur up to this passage
number.41
Isolation of tissue crude membranes fraction and
Western blot
Crude membrane fractions were prepared from untreated HRECs.
The multidrug-resistant, Pgp-overexpressing, variant HL60R of the
acute myeloid leukaemia cell line HL6043 was used as positive
control. Freshly confluent cells (2 106 cells) were washed with PBS
and lysed with ice-cold hypotonic lysing buffer (Saccharose 0.25 mM,
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Tris 10 mM, ethylendiaminetetraacetic acid 1 mM, pH 7.4) containing
protease inhibitors (Complete, Roche Diagnostics, Manheim,
Germany). After sonication for 20 s, homogenate was centrifugated
at 2000 g for 10 min. The supernatant was then centrifugated at
30 000 g for 30 min and the pellets containing the crude membranes
were resuspended in NaH2PO4 100 mM, MgCl2 10 mM, glycerol 20%,
pH 7.4 and stored at 801C until immunoblot analysis.
Proteins (40 mg for HRECs or 10 mg for HL60R cells) were
separated on sodiumdodecylsulfate-polyacrylamide gel electrophor-
esis gel. Pgp was detected by Western blot analysis according to
standard protocols or manufacturer’s instructions using C219
monoclonal antibody (10 mg/ml). A horseradish peroxidase-con-
jugated anti-mouse IgG was used as secondary antibody and Pgp
was revealed with enhanced chemiluminescence reagent (Amersham
Pharmacia Biotech, Piscataway, NJ, USA) according to the
manufacturer’s instructions.
Determination of Rhodamine-123 efflux
Rhodamine-123 (R-123) is a good fluorescent substrate for Pgp.44
Cellular efflux of R123 was used to evaluate the activity of Pgp using
an adaptation of the method proposed by Chieli et al.45 Confluent
cells cultured in 60 mm dishes were loaded for 1 h with 5 mg/ml
R123. The medium was then replaced by R123-free medium with or
without the Pgp inhibitors under investigation. For determination
of Pgp activity, R123 cellular concentration was quantified at 0, 30,
60, and 120 min after removal of R123 from the medium. For
evaluation of the inhibitory effect of sirolimus or cyclosporine on
Pgp function, the R123-containing medium was replaced by
medium containing cyclosporine or sirolimus and quantification
of the intracellular concentration of R123 was performed 30 min
after its removal. Cells were then washed three times with PBS, lysed
with 150ml ice-cold water and harvested with a rubber policeman.
Fluorescence intensity was measured with a spectrofluorimeter
(excitation 518 nm, emission 532 nm) and compared to a calibration
curve of pure R123. The amount of R123 obtained from cells was
corrected on the basis of protein content assessed by the
Bicinchroninic acid method (Pierce Chemicals, Rockford, IL, USA).
Cyclosporine cytotoxicity
HRECs were seeded in 96-well plates 103 cells/well. Twenty-four
hours later, cells were treated with cyclosporine or vehicle with or
without Pgp inhibitors (40mM verapamil, 5 mM PSC 833, 5 mg/ml
Pgp-4008, and 50 mM quinine).46,30–32 Six days later, the relative
number of living cells per well was determined on the basis of
mitochondrial integrity by assay with 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(Promega, Charbonnieres, France), according to the manufacturer’s
instructions. Cell death was determined by measuring the amount of
LDH released into the medium after treatment with cyclosporine.
LDH activity was determined by the CytoTox 96 non-radioactive
cytotoxicity assay (Promega, Charbonnieres, France) and quantified
by measuring absorbance at 490 nm.
Measurements of intracellular cyclosporine concentration
Freshly confluent cells cultured in 60 mm dishes were loaded with
0.5mM cyclosporine for 2 h. The medium was then replaced by
cyclosporine-free medium containing various concentrations of Pgp
inhibitors. Two hours later, cells were washed once with cold PBS
and harvested with a rubber policeman using 80 ml ice-cold PBS.
Intracellular cyclosporine was then measured by high-performance
liquid chromatography coupled with tandem mass spectrometry in
the positive ion, selected reaction monitoring mode, following the
transitions 1220/1203 and 1220/425 for cyclosporine, 1234/1217 and
1234/1199 for cyclosporine D (internal standard). The cell lysates
were diluted 1/5 with blank human serum, then proteins were
precipitated with acetone. Quantification was performed against a
calibration curve of cyclosporine in human serum. The limit of
quantitation was 10 ng/ml and the method was linear from this limit
of quantitation up to 2000 ng/ml (r2¼ 0.9981). Seven commercial
quality controls in whole blood at four levels between 100 and
1725 ng/ml were prepared as cell lysates, by 1/5 dilution in blank
serum, and analyzed in the same series as the cell samples. The
results showed that the method accuracy was very good, with bias
values between 8.6 and þ 8.7%.
Cyclosporine–sirolimus interaction
The cyclosporine–sirolimus interaction was assessed by measuring
cyclosporine cellular retention induced by sirolimus. Briefly, cells
loaded with 0.5mM cyclosporine for 2 h were incubated with
increasing sirolimus concentrations (0–5 mM) for 1 h. Cells were
then washed and harvested with a rubber policeman and intra-
cellular cyclosporine concentrations were quantified as described
above. Results were expressed as percentage of the initial intracellular
cyclosporine concentration before any cyclosporine efflux.
Statistical analysis
All data were expressed as the mean7s.e.m. of X3 separate
experiments in which triplicates were obtained, unless otherwise
specified. Statistical significance was tested by non-parametric tests
(Mann–Whitney U-test for unpaired comparisons and Wilcoxon’s
test for paired comparisons). Statistical analyses were performed
using Statview 5.0.1s software. P-values o0.05 were considered
significant.
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